$ARTH
Arch Therapeutics, Inc.

2023 Q1 Form 10-Q Financial Statement

#000185173423000065 Filed on February 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2021 Q4
Revenue $16.65K $6.261K $4.696K
YoY Change 432.08% 33.33%
Cost Of Revenue $18.72K $17.64K $16.79K
YoY Change 7.39% 5.02%
Gross Profit -$2.064K -$11.37K -$12.10K
YoY Change -85.57% -5.97%
Gross Profit Margin -12.39% -181.66% -257.58%
Selling, General & Admin $1.253M $1.103M $1.263M
YoY Change 3.63% -12.68% 41.89%
% of Gross Profit
Research & Development $170.6K $161.5K $234.6K
YoY Change -67.66% -31.18% -31.72%
% of Gross Profit
Depreciation & Amortization $380.00 $663.00 $799.00
YoY Change -52.44% -17.02% 114.78%
% of Gross Profit
Operating Expenses $1.423M $1.264M $1.498M
YoY Change -18.03% -15.58% 21.39%
Operating Profit -$1.425M -$1.276M -$1.510M
YoY Change -18.58% -15.5% 22.37%
Interest Expense $635.2K $524.3K $40.33K
YoY Change 1510.03% 1200.09% 37.8%
% of Operating Profit
Other Income/Expense, Net $523.0K -$524.3K -$40.33K
YoY Change -45.55% 1200.09% -150.61%
Pretax Income -$902.5K -$1.800M -$1.550M
YoY Change 14.19% 16.12% 34.32%
Income Tax
% Of Pretax Income
Net Earnings -$902.5K -$1.800M -$1.550M
YoY Change 14.19% 16.12% 34.32%
Net Earnings / Revenue -5418.98% -28750.3% -33009.94%
Basic Earnings Per Share -$0.71 -$1.44 -$1.31
Diluted Earnings Per Share -$0.71 -$1.44 -$6.547K
COMMON SHARES
Basic Shares Outstanding 1.263M 249.9M 237.2M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q1 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.50K $10.62K $1.088M
YoY Change -45.78% -99.02% 23.73%
Cash & Equivalents $29.50K $10.62K $1.088M
Short-Term Investments
Other Short-Term Assets $156.4K $288.9K $354.2K
YoY Change -13.26% -18.44% 79.69%
Inventory $1.402M $1.412M $1.198M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.588M $1.711M $2.536M
YoY Change 10.89% -32.52% 21.19%
LONG-TERM ASSETS
Property, Plant & Equipment $1.001K $1.381K $4.441K
YoY Change -72.52% -68.9% 6.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K $3.500K $3.500K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $4.501K $4.881K $7.941K
YoY Change -36.98% -38.53% 3.4%
TOTAL ASSETS
Total Short-Term Assets $1.588M $1.711M $2.536M
Total Long-Term Assets $4.501K $4.881K $7.941K
Total Assets $1.593M $1.716M $2.544M
YoY Change 10.65% -32.54% 21.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.426M $1.761M $748.9K
YoY Change 88.33% 135.22% 91.46%
Accrued Expenses $851.5K $493.7K $203.5K
YoY Change 444.68% 142.58% -30.78%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.436M $1.000M
YoY Change
Total Short-Term Liabilities $7.979M $4.145M $1.952M
YoY Change 452.39% 112.31% 162.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.754M $1.600M
YoY Change -100.0% 72.13% -6.92%
Other Long-Term Liabilities $0.00 $705.7K $1.415M
YoY Change -100.0% -50.13% -35.9%
Total Long-Term Liabilities $0.00 $3.460M $3.015M
YoY Change -100.0% 14.75% -23.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.979M $4.145M $1.952M
Total Long-Term Liabilities $0.00 $3.460M $3.015M
Total Liabilities $7.979M $7.605M $4.967M
YoY Change 77.35% 53.1% 6.39%
SHAREHOLDERS EQUITY
Retained Earnings -$57.78M -$56.87M -$51.35M
YoY Change 10.81% 10.76%
Common Stock $51.39M $50.98M $236.8K
YoY Change 21590.54% 21430.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.386M -$5.889M -$2.424M
YoY Change
Total Liabilities & Shareholders Equity $1.593M $1.716M $2.544M
YoY Change 10.65% -32.54% 21.13%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$902.5K -$1.800M -$1.550M
YoY Change 14.19% 16.12% 34.32%
Depreciation, Depletion And Amortization $380.00 $663.00 $799.00
YoY Change -52.44% -17.02% 114.78%
Cash From Operating Activities -$599.9K -$650.1K -$1.179M
YoY Change -41.97% -44.84% 4.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 618.8K -$86.26K $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -599.9K -$650.1K -$1.179M
Cash From Investing Activities 0.000
Cash From Financing Activities 618.8K -$86.26K $0.00
Net Change In Cash 18.89K -$736.3K -$1.179M
YoY Change -101.83% -37.52% 1375.07%
FREE CASH FLOW
Cash From Operating Activities -$599.9K -$650.1K -$1.179M
Capital Expenditures $0.00
Free Cash Flow -$1.179M
YoY Change 4.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001537561
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
255309 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
238425 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
127781 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
748275 usd
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
748275 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4145167 usd
CY2022Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2362273 usd
CY2022Q4 arch Interest Payable Noncurrent
InterestPayableNoncurrent
246489 usd
CY2022Q3 arch Interest Payable Noncurrent
InterestPayableNoncurrent
204575 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
459200 usd
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
459200 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3459717 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3476048 usd
CY2022Q4 us-gaap Liabilities
Liabilities
7604884 usd
CY2022Q3 us-gaap Liabilities
Liabilities
6796542 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
4000000
CY2021Q4 us-gaap Cost Of Revenue
CostOfRevenue
16792 usd
CY2021Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1263104 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
234618 usd
CY2021Q4 us-gaap Costs And Expenses
CostsAndExpenses
1514514 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1509818 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-524313 usd
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40329 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1800056 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1550147 usd
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2022Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1249432
CY2021Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1183946
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1800056 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104026 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5888833 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-1025674 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1550147 usd
CY2021Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q4 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
152143 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2423678 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1800056 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1550147 usd
CY2022Q4 us-gaap Depreciation
Depreciation
663 usd
CY2021Q4 us-gaap Depreciation
Depreciation
799 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
104026 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
152143 usd
CY2022Q4 us-gaap Paid In Kind Interest
PaidInKindInterest
371755 usd
CY2021Q4 us-gaap Paid In Kind Interest
PaidInKindInterest
0 usd
CY2022Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3211 usd
CY2021Q4 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-375 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-147492 usd
CY2021Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
46886 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
433482 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
340797 usd
CY2022Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
152558 usd
CY2021Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
40329 usd
CY2022Q4 arch Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-63196 usd
CY2021Q4 arch Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-115935 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-650065 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1178525 usd
CY2022Q4 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
106257 usd
CY2021Q4 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
CY2022Q4 arch Proceeds From Convertible Notes Warrants And Common Stock Net Of Financing Costs
ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts
20000 usd
CY2021Q4 arch Proceeds From Convertible Notes Warrants And Common Stock Net Of Financing Costs
ProceedsFromConvertibleNotesWarrantsAndCommonStockNetOfFinancingCosts
0 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-86257 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-736322 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1178525 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
746940 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2266639 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10618 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1088114 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Use Of Estimates
UseOfEstimates
<span style="text-decoration: underline; ">Use of Estimates</span>Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.
CY2022Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="text-decoration: underline; ">Concentration of Credit Risk</span>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33756 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33756 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32375 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31712 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1381 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2044 usd
CY2022Q4 us-gaap Depreciation
Depreciation
663 usd
CY2021Q4 us-gaap Depreciation
Depreciation
799 usd
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9063 usd
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1405785 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
1414848 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
98626
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.00
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y5M15D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16900 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
24500
CY2022Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18801
CY2022Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
70.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
104325
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3900 usd
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
68202
CY2022Q4 arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
54.00
CY2022Q4 arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P1Y6M
CY2022Q4 arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
975 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
104325
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
40.00
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P1Y3M3D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3900 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
18.00
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
20.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
-0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
18.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
20.00
CY2016Q3 arch Shelf Registration Statement Maximum Amount Authorized
ShelfRegistrationStatementMaximumAmountAuthorized
50000000 usd
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
215625
CY2022Q3 arch Percentage Of Principal Amount
PercentageOfPrincipalAmount
0.15 pure
CY2022Q3 arch Proceeds From Issuance Of Convertible Notes Common Stock And Warrants Gross
ProceedsFromIssuanceOfConvertibleNotesCommonStockAndWarrantsGross
3500000 usd
CY2022Q3 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
775000 usd
CY2022Q3 arch Placement Agents Fees
PlacementAgentsFees
555000 usd
CY2022Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4000000

Files In Submission

Name View Source Status
arch-20221231_cal.xml Edgar Link unprocessable
0001851734-23-000065-index-headers.html Edgar Link pending
0001851734-23-000065-index.html Edgar Link pending
0001851734-23-000065.txt Edgar Link pending
0001851734-23-000065-xbrl.zip Edgar Link pending
arch-20221231.xsd Edgar Link pending
arch20221231_10q.htm Edgar Link pending
ex_466246.htm Edgar Link pending
ex_466247.htm Edgar Link pending
ex_466248.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
arch-20221231_def.xml Edgar Link unprocessable
arch-20221231_lab.xml Edgar Link unprocessable
arch-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
arch20221231_10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending